All Stories

  1. Late D-Chiro-Inositol Treatment Has Limited Effects on Hippocampal Alterations in Aged 3×Tg-AD Mice: Partial Rescue of CA1 Neurons Without Recovery of the Dentate Gyrus–CA3 Circuit
  2. Pre-infusion quantitative EEG features associated with delayed neurocognitive impairment following CAR T-cell therapy
  3. Effectiveness and safety of cannabidiol in adult patients with epilepsy: A multicenter, retrospective study
  4. Peripheral Inflammatory Biomarkers in Chronic Autoimmune-Associated Epilepsy: An Exploratory Case–Control Study
  5. Plasma p-tau217 measured by the Elecsys automated immunoassay: Prospective validation in a heterogeneous memory clinic cohort
  6. Implementación del Código Crisis para la atención urgente de la epilepsia en España: un protocolo asistencial integral
  7. Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice
  8. Safranal-Standardized Saffron Extract Improves Metabolic, Cognitive, and Anxiolytic Outcomes in Aged Mice via Hypothalamic–Amygdalar Peptide Modulation
  9. Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour
  10. Long-term Impact of Cenobamate on Cognition in Patients with Drug-Resistant Focal Epilepsy: Outcomes from an Exploratory Real-World Study
  11. Prior restraint stress counteracts memory deficits associated with adolescent alcohol exposure by targeting both the hippocampal endocannabinoid and glutamatergic systems
  12. Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3×Tg Humanized Mouse Model of Alzheimer’s Disease
  13. Late-onset Rasmussen encephalitis: 3 illustrative cases and a review of the literature
  14. Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV‐add study
  15. Cataract Surgery in Cognitive Impairment: Navigating the Accessibility Challenge in European Healthcare
  16. Tratamiento de la crisis epiléptica en el ámbito no sanitario: tiempo de tratar (TT)
  17. Peripheral expression of NPY1R-based heteroreceptor complexes reflects hippocampal neuroimmune status: Novel biomarkers for early Alzheimer’s disease detection
  18. Relapses in Anti-NMDAR Encephalitis
  19. Inflammatory Drug-Resistant Epilepsy Index (IDREI) as a Molecular Compound Biomarker in Focal Epilepsies
  20. Proposal of an Inflammatory Drug‐Resistant Epilepsy Index (Idrei) as Molecular Composed Biomarker in Focal Epilepsies
  21. Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis
  22. Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐TOLE) in adults with focal epilepsy
  23. Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease
  24. Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy
  25. Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology
  26. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  27. Pronóstico funcional de pacientes con NORSE y FIRES tratados con inmunoterapia: revisión sistemática
  28. A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis
  29. Impact of inflammation on cognitive function in patients with highly inflammatory rheumatoid arthritis
  30. Biomarkers of Neuroinflammation and Epileptogenesis: A Systematic Review
  31. Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats
  32. Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus
  33. Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder
  34. Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus
  35. Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions
  36. Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study
  37. Neuropeptide Y receptor 1 and galanin receptor 2 (NPY1R-GALR2) interactions in the dentate gyrus and their relevance for neurogenesis and cognition
  38. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study
  39. Epileptic and neurodevelopmental encephalopathy associated to SYNGAP1 mutation: Description of a case and treatment response to cannabidiol
  40. Encefalopatía epiléptica y del desarrollo asociada a mutación del SYNGAP1: descripción de un caso y respuesta al tratamiento con cannabidiol
  41. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy
  42. Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies
  43. Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices
  44. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  45. Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations
  46. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis
  47. Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program
  48. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder
  49. Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices
  50. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy
  51. Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: A systematic review
  52. Longitudinal Study of Cognitive Functioning in Adults with Juvenile Idiopathic Arthritis
  53. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  54. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  55. Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
  56. The cognitive and psychiatric subacute impairment in severe Covid-19
  57. Fracaso de un anticuerpo monoclonal anti-CGRP en el tratamiento de la migraña. ¿Tiene sentido probar otro?
  58. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis
  59. The Cognitive and Psychiatric Subacute Impairment in severe Covid-19.
  60. Prevalence of Neural Autoantibodies in Paired Serum and Cerebrospinal Fluid in Adult Patients with Drug-Resistant Temporal Lobe Epilepsy of Unknown Etiology
  61. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA)
  62. The Cognitive and Psychiatric Subacute Impairment in severe Covid-19.
  63. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
  64. Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain
  65. Efectos de la pandemia por Covid-19 sobre la calidad de vida de los pacientes con Esclerosis Lateral Amiotrófica
  66. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  67. Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis
  68. GABAergic deficits in absence of LPA1 receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus
  69. Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis
  70. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  71. Emergency implementation of telemedicine for epilepsy in Spain: Results of a survey during SARS-CoV-2 pandemic
  72. Miller‐Fisher syndrome after SARS‐CoV‐2 infection
  73. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases
  74. Reader response: Neurologic complications of coronavirus infections
  75. Ofatumumab versus Teriflunomide in Multiple Sclerosis
  76. Neuroplasticity and Epilepsy Surgery in Brain Eloquent Areas: Case Report
  77. Implantación emergente de un servicio de Teleneurología en la Unidad de Neuromuscular del Hospital Regional de Málaga durante la pandemia por SARS-CoV-2
  78. Análisis de letalidad por COVID-19 en pacientes con demencia neurodegenerativa
  79. Incidence and case fatality rate of COVID-19 in patients with active epilepsy
  80. Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?
  81. ¿Va a cambiar la neurología tras la pandemia de COVID-19 en los próximos 5 años? Estudio de enfoque mediante informadores clave
  82. Response to immunotherapy in anti‐IgLON5 disease: A systematic review
  83. Evaluación prequirúrgica mediante resonancia magnética funcional en pacientes con tumores neuroepiteliales disembrioplásicos: una serie de casos
  84. Clinical outcomes of eslicarbazepine acetate monotherapy for focal‐onset seizures: A multicenter audit
  85. Epileptic encephalopathy with phenotype pseudo-Dravet and missense mutation in the GRIN2A gene
  86. Miastenia grave inducida por tratamiento con inhibidores del punto de control inmunológico: primer caso secundario a avelumab y revisión de casos previamente publicados
  87. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN
  88. Consenso Delphi EPICON: recomendaciones sobre el manejo adecuado del cambio a acetato de eslicarbazepina en epilepsia
  89. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review
  90. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures
  91. Estudio observacional multicéntrico español sobre el empleo de fármacos antiepilépticos en consultas de neurología
  92. Epidemiología de la epilepsia en España y Latinoamérica
  93. Eslicarbazepine acetate and carotid intima-media thickness in epileptic patients
  94. Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
  95. Awagrafia
  96. Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
  97. Recomendaciones para el abordaje multidisciplinar del complejo esclerosis tuberosa
  98. Cognitive Profile of Zonisamide and Valproic Acid in the Treatment of Idiopathic Generalized Epilepsy: A Comparative Observational Study
  99. Adhesión al tratamiento con levetiracetam: estudio observacional retrospectivo no intervencionista
  100. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial
  101. Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature
  102. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
  103. Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study
  104. Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015
  105. Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study
  106. Analysis of Factors Influencing Telephone Call Response Rate in an Epidemiological Study
  107. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide
  108. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
  109. Characteristics of temporal lobe epilepsy with no ictal impairment of consciousness
  110. Spatial recognition memory in a virtual reality task is altered in refractory temporal lobe epilepsy
  111. The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES)
  112. Validación en castellano de un cuestionario breve útil para cribado epidemiológico de epilepsia en España: Cuestionario EPIBERIA
  113. Acetato de eslicarbazepina en la práctica clínica. Resultados de eficacia y seguridad
  114. Zonisamida en el tratamiento de la epilepsia: revisión de la bibliografía desde la terapia añadida a la monoterapia
  115. Consenso de las Recomendaciones de Actuación diagnóstica y Terapéutica sobre Epilepsia resistente a fármacos antiepilépticos en España (Consenso RATE-España)
  116. Predictive model for refractoriness in Temporal Lobe Epilepsy based on clinical and diagnostic test data
  117. Cajal’s first steps in scientific research
  118. Spatial navigation impairment in patients with refractory temporal lobe epilepsy: Evidence from a new virtual reality-based task
  119. Factores vinculados a la adhesión al tratamiento en pacientes con epilepsia refractaria y no refractaria
  120. Antiepileptic treatment in patients with epilepsy and other comorbidities
  121. Vohwinkel Syndrome secondary to missense mutation D66H in GJB2 gene (connexin 26) can include epileptic manifestations
  122. Amnesia topográfica transitoria: descripción de una serie de ocho casos
  123. Possible case of peripheral osmotic demyelination syndrome
  124. Driving cost factors in adult outpatients with refractory epilepsy: A daily clinical practice in clinics of neurology in Spain
  125. Guía de práctica clínica de la Sociedad Andaluza de Epilepsia sobre profilaxis y tratamiento de las crisis epilépticas sintomáticas agudas
  126. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia sobre prescripción de fármacos antiepilépticos genéricos
  127. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia: recomendaciones terapéuticas ante una crisis epiléptica y en el estado epiléptico
  128. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia para el diagnóstico y tratamiento del paciente con una primera crisis epiléptica en situaciones de urgencia
  129. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: A cost-of-illness study (LINCE study)
  130. Possible case of peripheral osmotic demyelination syndrome
  131. Incidencia de ictus en España. Bases metodológicas del estudio Iberictus
  132. Pseudomigraña con pleocitosis y la ‘invisibilidad’ de las descripciones originales en castellano
  133. Clinical Implications of Mechanisms of Resistance to Antiepileptic Drugs
  134. Stiff person syndrome (SPS), a basal ganglia disease? Striatal MRI lesions in a patient with SPS
  135. Bilateral Bell Palsy and Acute HIV Type 1 Infection: Report of 2 Cases and Review
  136. Menstrual Tension-Type Headache: Evidence for Its Existence.
  137. A transcranial doppler study in interictal migraine and tension-type headache
  138. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  139. Encefalomielitis aguda diseminada por picadura de himenóptero
  140. Avances en el conocimiento de la etiología y la fisiopatología de las epilepsias reflejas
  141. Cirugía de la epilepsia del lóbulo temporal: ¿es suficiente eliminar las crisis?
  142. Trombólisis en el ictus: la accesibilidad sin garantía de seguridad es insostenible
  143. Regarding: 'Mosaicism and seizure onset in ring chromosome 20 syndrome'
  144. The Red Ear Syndrome: Five New Cases
  145. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: II. Terapéutica antiepiléptica crónica en el adulto y en el niño
  146. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: III. Tratamiento antiepiléptico en situaciones especiales
  147. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: I. Criterios de inicio y cese y bases farmacológicas del tratamiento antiepiléptico
  148. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: IV. Principios generales de politerapia antiepiléptica y estrategias terapéuticas en epilepsia refractaria
  149. Doppler transcraneal en el diagnóstico de fístula arteriovenosa pulmonar
  150. Infarto maligno de la arteria cerebral media: ¿tratamiento médico o quirúrgico?
  151. Hemorragia cerebral múltiple y antiagregantes plaquetarios
  152. Ring chromosome 20 epilepsy syndrome in children: Electroclinical features
  153. Paciente de 45 años con epilepsia refractaria del lóbulo temporal desde la infancia
  154. Epilepsia refractaria del adulto
  155. Comment: Fluorouracil-Induced Aphasia: Neurotoxicity versus Cerebral Ischemia
  156. Comment: fluorouracil-induced aphasia: neurotoxicity versus cerebral ischemia
  157. Epilepsia parcial refractaria a tratamiento médico y lesión porencefálica occipital
  158. Controversias en torno a los nuevos fármacos antiepilépticos
  159. El diagnóstico de la enfermedad cervical espondilótica: una revisión basada en la evidencia
  160. Caracterización epidemiológica de la epilepsia del adulto subsidiaria de ingreso hospitalario
  161. Pseudotumor inflamatorio: diagnóstico diferencial de los tumores del IV ventrículo
  162. Cromosoma 20 en anillo: ¿Una canalopatía epiléptica?
  163. Ischemic Stroke following Cisplatin and 5-Fluorouracil Therapy: A Transcranial Doppler Study
  164. Descripción histórica de la asociación de macroorquídia, retraso mental y dismorfia craneal en varones (Síndrome del cromosoma X frágil) por A. B. Richerand
  165. Hemodinámica cerebral en el síndrome de pseudomigraña con pleocitosis de LCR: un estudio Doppler transcraneal
  166. El diagnóstico de la esclerosis temporal mesial mediante imagen de resonancia magnética
  167. Correlación genotipo-fenotipo en la distrofia miotónica y predicción de la gravedad clínica
  168. Hemiatrofia facial progresiva de Parry-Romberg: consideraciones patogénicas y evolutivas a propósito de un caso con seguimiento prolongado
  169. Esclerosis temporal mesial (II): manifestaciones clínicas y estudios complementarios
  170. Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases
  171. Mediterranean spotted fever with central and peripheral neurological complications